Original Article

Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature

Takashi Ito¹,², Masahiro Yamamura³, Toshihiro Hirai⁴, Takashi Ishikawa⁵, Tatsuo Kanda⁶, Takuya Nakai⁷, Mizuka Ohkouchi¹, Yuka Hashikura¹, Koji Isozaki¹, Seiichi Hirota¹

¹Department of Surgical Pathology, Hyogo College of Medicine, Hyogo, Japan; ²Department of Pathology, Sanda Municipal Hospital, Hyogo, Japan; ³Department of Clinical Oncology, Kawasaki Medical School, Okayama, Japan; ⁴Department of Surgery, Division of Gastroenterology, Kawasaki Medical School, Okayama, Japan; ⁵Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; ⁶Department of Surgery, Sanjo General Hospital, Niigata, Japan; ⁷Department of Surgery, Faculty of Medicine, Kinki University, Osaka, Japan

Received September 22, 2014; Accepted November 8, 2014; Epub October 15, 2014; Published November 1, 2014

Abstract: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the human gut. Most sporadic GISTs have somatic gain-of-function mutations of the c-kit gene. The mutations are frequently found at exon 11, sometimes at exon 9 and rarely at exon 13 or 17. Recently, exon 8 c-kit gene mutations were reported in very minor proportion of sporadic GISTs. We also found 3 GISTs with exon 8 c-kit gene mutations in approximately 1,000 sporadic GISTs examined. In the present report, we showed the clinicopathological data of those GISTs. One case had a deletion of codon 419 of aspartate, and 2 cases had a substitution of 3 amino acids of codon 417 to codon 419 to tyrosine. The former was the same mutation recently reported in 2 GIST cases, but the latter has not been reported in any GISTs. All three cases occurred at extragastric sites and two of three showed distant metastasis. Since the remaining case was regarded as high risk for recurrence, imatinib adjuvant treatment has been done without evidence of metastasis. Our results confirmed the idea that exon 8 mutations are minor but actually existing abnormalities in sporadic GISTs, and suggested that such GISTs have a feature of extragastric development and a metastasis-prone nature. Since the exon 8 mutations appeared to be really sensitive to imatinib as shown in the present case study, accurate genotyping including exon 8 of the c-kit gene is necessary in GISTs to predict response to imatinib in both the unresectable/metastatic and adjuvant settings.

Keywords: c-kit gene, exon 8, gain-of-function mutation, GIST, imatinib, sunitinib

Introduction

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the human gut. Most GISTs express a receptor tyrosine kinase (TK), KIT [1, 2], encoded by proto-oncogene c-kit [3-6]. Interstitial cells of Cajal (ICC), which are present in the gastrointestinal (GI) wall and regulate the GI motility through their spontaneous impulse generation [7], are also positive for KIT. Since ICCs are the only proper cells in GI tract that express KIT, GISTs are now considered to originate from ICCs or precursor of ICCs.

KIT consists of an extracellular (EC) domain with five immunoglobulin-like repeats, a transmembrane domain, a juxtamembrane (JM) domain, and TK I and II domains split by the kinase insert [3-6]. A ligand for KIT is stem cell factor (SCF) [8-10]. The binding of SCF and KIT induces autophosphorylation of KIT, and its downstream pathways such as Ras-MAPK, PI3K-Akt and Jak-Stat systems are activated to induce proliferation and differentiation of ICCs, mast cells, melanocytes, germ cells and erythroblasts. On the other hand, gain-of-function mutations of the c-kit gene cause constitutive autophosphorylation of KIT without SCF stimulation, and subsequently activate the downstream signaling molecules. Thus, the gain-of-function mutations could be a cause of GISTs, mast cell neoplasms, seminomas, melanomas...
Exon 8 c-kit gene mutation in GISTs

Imatinib is a selective TK inhibitor for KIT and PDGFRA [24], which is clinically used for treatment of metastatic or unresectable GISTs [25]. It generally shows a remarkable effect on most GIST cases, but its effectiveness is well-known to be dependent on the types of the c-kit and PDGFRA gene mutations [26, 27]. Most GISTs with exon 11 c-kit gene mutations show best response to imatinib treatment whereas the particular type of the PDGFRA gene mutation at exon 18, a substitution of aspartate to valine at codon 842 (Asp842Val), is resistant to imatinib [19]. Imatinib is now being used for GISTs after complete resection when they are regarded as high risk tumors for recurrence [28]. On the other hand, sunitinib and regorafenib are multi-targeted TK inhibitors. After the failure of imatinib treatment, sunitinib is administered as a second-line drug [29] and regorafenib as a third-line one in GISTs [30].

In contrast with sporadic GISTs, most of the c-kit gene mutations are present at exon 17 in sporadic mast cell neoplasms. However, some sporadic mast cell neoplasms have mutations at exon 9, at exon 11 and even at exon 8 [31]. Recently, moreover, exon 8 c-kit gene mutations were also reported in very minor proportion of sporadic GIST cases [32]. Types of exon 8 c-kit gene mutations reported in mast cell neoplasms are various [31], but deletion of aspartate at codon 419 (Del-Asp419) is the only type of exon 8 c-kit gene mutation reported in GISTs [32]. In the present study, we examined whether GISTs have exon 8 c-kit gene mutations in approximately 1,000 sporadic cases, and found 3 such cases. One case had Del-Asp419 and two had substitution of 3 amino acids of codon 417 to codon 419 to tyrosine, hereafter designated as ThrTyrAsp (417-419) Tyr. Here, we showed clinicopathological features of these GISTs.

Materials and methods

Analyses of c-kit and PDGFRA gene mutations

We have analyzed c-kit and PDGFRA gene mutations in approximately 1,000 authentic GIST cases. When fresh-frozen samples were available, total RNA was extracted using RNeasy Mini Kit (QIAGEN, Valencia, CA). Almost all coding regions of the c-kit and PDGFRA genes were amplified by polymerase chain
Exon 8 c-kit gene mutation in GISTs

Table 1. Clinicopathological characteristics of GISTs with exon 8 c-kit gene mutations

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age</th>
<th>Sex</th>
<th>Size (cm)</th>
<th>Site</th>
<th>KIT</th>
<th>CD34</th>
<th>Mitosis/50HPFs</th>
<th>Metastasis</th>
<th>Survival period (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>53</td>
<td>M</td>
<td>8.0</td>
<td>SI</td>
<td>+</td>
<td>+</td>
<td>51</td>
<td>+ (B)</td>
<td>159 (dead)</td>
</tr>
<tr>
<td>2</td>
<td>56</td>
<td>M</td>
<td>3.5</td>
<td>D</td>
<td>+</td>
<td>_</td>
<td>13</td>
<td>+ (L, P)</td>
<td>102 (dead)</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>M</td>
<td>8.5</td>
<td>D</td>
<td>+</td>
<td>+</td>
<td>32</td>
<td>_</td>
<td>29 (alive)</td>
</tr>
</tbody>
</table>

HPF, high power field; M, male; SI, small intestine; D, duodenum; B, bone; L, liver; P, peritoneum. *Survival period after the first GIST resection; †This case is during adjuvant imatinib therapy.

Clinicopathological features of GISTs with exon 8 c-kit gene mutations

Brief clinicopathological features of 3 GIST cases with exon 8 c-kit gene mutations were shown in Table 1. Characteristically, all GISTs with the mutation occurred outside the stomach (2 at the duodenum and 1 at the small intestine). All three tumors consisted of spindle shaped cells (Figure 2A, 2D and 2G). Immunohistochemistry revealed that the tumor cells of all cases were diffusely and strongly positive for KIT (Figure 2B, 2E and 2H). CD34 was positive in cases 1 and 3 but negative in case 2 (Figure 2C, 2F and 2I). All three GISTs had high mitotic figures (Table 1), suggesting that they were highly aggressive. In fact, two of three GISTs showed metastasis. The patient of case 3 has been receiving imatinib adjuvant therapy until now, and no recurrence is evident.

Clinical history of patients with exon 8 c-kit gene mutations

Case 1: A 53-year-old Japanese man received partial resection of the small bowel for small intestinal GIST (8.0 cm in diameter) which had Del-Asp419 at exon 8 of the c-kit gene. A focus of GIST metastasis developed at the 5th thoracic vertebra approximately 7 years after the complete resection of the primary tumor. He underwent partial resection of the metastatic lesion, but the remaining tumor at the metastatic site enlarged 9 months after the partial metastatectomy. Imatinib therapy (400 mg/day) was started, and size of the metastatic lesion decreased. However, the metastatic tumor regrew 22 months after the initial imatinib administration, and imatinib was changed to sunitinib. The imatinib-resistant lesion had been controlled during 16 months under sunitinib administration. The metastatic tumor grew again, and it was resected as far as possible. In spite of multidisciplinary therapy including rein-

reaction (PCR) after reverse transcription of the extracted RNA as described previously [1, 19]. When fresh-frozen samples were not available, genomic DNA was extracted from paraffin sections using QIAamp DNA Mini Kit (QIAGEN). Exons 8, 9, 11, 13 and 17 of the c-kit gene and exons 12, 14 and 18 of the PDGFRA gene were amplified by PCR. Primers used for PCR were as described previously [17, 19], and a forward primer of 5'-CCATTTCTGTTTTCCTGTAG-3' and a reverse primer of 5'-CTCTGCATTATAAGCAGTG-3' were used for genomic DNA analysis at exon 8 of the c-kit gene. Direct sequencing of the amplified products was carried out with ABI BigDye terminator ver.3.1 (Applied Biosystems, Foster City, CA) and ABI Prism 3100-Avant Genetic Analyzer (Applied Biosystems). The informed consent for the present study was obtained, and the study was approved by the institutional review boards.

Histology and immunohistochemistry of GISTs

Resected GIST tissues were fixed with 10% formalin and embedded in paraffin. Sections (3 micrometer thick) were cut and used for hematoxylin and eosin staining and immunohistochemistry. Immunohistochemistry was performed using ENVISION+ KIT HRP (DAB) system (DAKO, Glostrup, Denmark). Rabbit polyclonal antibody against human KIT (A4502; DAKO) and mouse monoclonal antibody against human CD34 (Novocastra Laboratories, Newcastle upon Tyne, UK) were used as the primary antibodies.

Results

Detection of exon 8 c-kit gene mutations

We examined whether exon 8 c-kit gene mutations were detected in approximately 1,000 sporadic GISTs. Among them, one GIST had Del-Asp419 and 2 GISTs had ThrTyrAsp (417-419) Tyr (Figure 1A and 1B).
Exon 8 c-kit gene mutation in GISTs

Introduction of imatinib or sunitinib, irradiation, and metastatectomy, the drug-resistant remaining lesion could not be controlled. He died 13 years and 3 months after the first operation for small intestinal GIST. Sequencing of c-kit cDNA derived from the resected samples revealed that the sunitinib-resistant lesion had second Asp822Lys at exon 17 in addition to Del-Asp419. Imatinib- and sunitinib-resistant characteristics are considered to be resulted from this second mutation.

Case 2: A 56-year-old Japanese man underwent partial resection of the duodenum for duodenal GIST (3.5 cm in diameter) which showed ThrTyrAsp (417-419) Tyr at exon 8 of the c-kit gene. Two years after the complete resection of duodenal GIST, multiple liver metastases were found by abdominal CT. Imatinib administration (400 mg/day) was started, and the metastatic foci had been controlled for 18 months. Because of regrowth of one of the metastatic foci in the liver, partial hepatectomy was performed. In spite of continuation of imatinib administration after the metstatectomy, peritoneal masses developed. Although the peritoneal lesions were resected, multiple peritoneal masses developed again. He received sunitinib therapy with 4 month control period. After the failure of sunitinib, regorafenib was administered on clinical trial, but it showed no apparent effect. He died 8 years and 4 months after the first operation for duodenal GIST. Sequencing of c-kit cDNA derived from the imatinib-resistant hepatic tumor and peritoneal tumor revealed that both lesions had Asp910Tyr at

Figure 2. Histopathology and immunohistochemistry of 3 GISTs with exon 8 c-kit gene mutations. A. Hematoxylin and eosin staining reveals that the tumor cells in case 1 are spindle-shaped. B. Tumor cells in case 1 are immunohistochemically KIT-positive. C. Tumor cells in case 1 are also immunohistochemically CD34-positive. D. Tumor cells in case 2 are spindle-shaped by hematoxylin and eosin staining. E. Immunohistochemistry reveals that tumor cells in case 2 are KIT-positive. F. Immunohistochemistry reveals that tumor cells in case 2 are CD34-negative. G. Hematoxylin and eosin staining shows that the tumor cells in case 3 are spindle-shaped. H. Tumor cells in case 3 are immunohistochemically KIT-positive. I. Tumor cells in case 3 are immunohistochemically CD34-positive.
Exon 8 c-\textit{kit} gene mutation in GISTs

Exon 18 in addition to ThrTyrAsp (417-419) Tyr at exon 8. This second mutation is considered to be a cause of imatinib-resistant character.

\textbf{Case 3}: A 41-year-old Japanese man received pancreaticoduodenectomy for duodenal GIST (8.5 cm in diameter) which had ThrTyrAsp (417-419) Tyr at exon 8 of the c-\textit{kit} gene. Since it was judged as a high risk tumor for recurrence, adjuvant imatinib treatment (400 mg/day) has been done for 29 months after the operation. At present, he is under imatinib treatment and there is no evidence of recurrence.

\textbf{Discussion}

We reported here 3 cases of sporadic GISTs with exon 8 c-\textit{kit} gene mutations. Frequency of the mutations is low (approximately 0.3%), but at least 3 GISTs really had two types of the mutations such as Del-Asp419 and ThrTyrAsp (417-419) Tyr.

Exon 8 c-\textit{kit} gene mutations was first reported in acute myeloid leukemia in 1999 [33]. In acute myeloid leukemia [33, 34], various types of exon 8 c-\textit{kit} gene mutations are known including ThrTyr (417&418) His, ThrTyrAsp (417-419) Asn, ThrTyrAsp (417-419) Ile, ThrTyrAsp (417-419) Phe, ThrTyrAsp (417-419) Tyr, ThrTyrAsp (417-419) Val, ThrTyrAsp (417-419) ArgAla, ThrTyrAsp (417-419) ArgGly, TyrAsp (418&419) Gly, TyrAsp (418&419) Ser, Asp-419Phe, Del-Asp419 and AspArg (419&420) PhePheAspGly. In pediatric mastocytosis, on the other hand, exon 8 c-\textit{kit} gene mutations were reported in 2010 [31]. The types of the exon 8 c-\textit{kit} gene mutations reported in pediatric mastocytosis are Del-Asp419, Ins-PhePhe between codon418 and codon419, ThrTyrAsp (417-419) Tyr and Cys443Tyr [31]. Many types of exon 8 c-\textit{kit} gene mutations are common in acute myeloid leukemia and pediatric mastocytosis. Although acute myeloid leukemia does not appear to have any highly frequent mutation types, Del-Asp419 appears to be the most frequent mutation type in pediatric mastocytosis.

Exon 8 c-\textit{kit} gene mutations in GISTs were first reported in familial GIST cases with germline c-\textit{kit} gene mutation in 2005 [23], and the type of the mutation was Del-Asp419. The patients in the family members had not only multiple GISTs but also mastocytosis. Recently, 2 sporadic GIST cases with Del-Asp419 were found [32]. Therefore, Del-Asp419 was the only mutation type reported in GISTs with exon 8 c-\textit{kit} gene mutation. In the present study, we reported one GIST case with Del-Asp419 and 2 GISTs cases with ThrTyrAsp (417-419) Tyr. Described above, ThrTyrAsp (417-419) Tyr has been reported in acute myeloid leukemia and sporadic pediatric mast cell neoplasms [31, 33, 34]. Thus, these are the first reported GIST cases with ThrTyrAsp (417-419) Tyr among sporadic and familial GIST cases.

In the previous report, 2 sporadic GISTs with exon 8 c-\textit{kit} gene mutations occurred at the small bowel [32]. In the present study, 3 GISTs with exon 8 c-\textit{kit} gene mutations were present at the duodenum in 2 cases and at the small intestine in 1 case. Since all of the reported GIST cases with exon 8 c-\textit{kit} gene mutations developed at the small intestine or duodenum, those GISTs appear to arise from extragastric sites. However, the number of GIST cases with exon 8 c-\textit{kit} gene mutations is too small to draw conclusions, and further effort to collect those GIST cases is needed.

In the previous report of sporadic GISTs with exon 8 c-\textit{kit} gene mutations, one GIST developed multiple metastatic foci in the peritoneum [32]. The other case did not show metastasis. However, the patient had been receiving adjuvant imatinib therapy because the tumor was regarded as intermediate to high risk for recurrence [32]. In the present study, 2 cases of GISTs with exon 8 c-\textit{kit} gene mutations showed distant metastasis; one was in bone and the other was in liver and peritoneum. The other case in this study does not show metastasis, but the patient also has been receiving adjuvant imatinib therapy because the tumor was classified as high risk for recurrence. These results suggested that GISTs with exon 8 c-\textit{kit} gene mutations might be prone to be metastatic. In fact, all 3 cases in the present study had high mitotic figures, suggesting GISTs with exon 8 c-\textit{kit} gene mutations might be aggressive. More cases with exon 8 c-\textit{kit} gene mutations have to be collected to clarify the possibility.

In the previous report, exon 8 c-\textit{kit} gene mutations such as Del-Asp419, ThrTyrAsp (417-419) Tyr, Cys443Tyr, and ThrTyrAsp (417-419) Ile were demonstrated to be ligand-independently autophosphorylated [25, 31, 34]. In the previous report, moreover, exon 8 c-\textit{kit} gene mutations of Del-Asp419 and ThrTyrAsp (417-419) Ile
Exon 8 c-kit gene mutation in GISTs

were demonstrated to be sensitive to imatinib in vitro [25, 34]. As described above, imatinib was reported to be administered to one sporadic GIST case with Del-Asp419 because of being regarded as intermediate to high risk for recurrence [32]. The patient did not show recurrence for 24 months under adjuvant imatinib treatment, but the case cannot clearly demonstrate whether the mutation is sensitive to imatinib in vivo. On the other hand, our 2 cases with distant metastasis showed apparent clinical effect of imatinib. Recently, imatinib tends to be selectively used only for GISTs with imatinib-sensitive mutations. In many GIST cases, the mutations are usually examined only at exons 9, 11, 13 and 17 of the c-kit gene and exon 12, 14, 18 of the PDGFRα gene. Therefore, GISTs with exon 8 c-kit gene mutation could be erroneously regarded as so-called wild-type GISTs which are usually resistant to imatinib, and those cases might not be considered to be candidates for imatinib treatment. We have to examine whether the exon 8 c-kit gene mutations are present in so-called wild-type GISTs to prevent loss of opportunity for imatinib treatment in those patients.

Asp816Val c-kit gene mutation at exon 17 is often observed in sporadic mast cell neoplasms [11, 12]. However, any GISTs have not been reported to possess this mutation. Namely, there is tumor-type specificity in Asp816Val. However, this is an exceptional correlation between tumor-types and particular mutations. Many types of the c-kit gene mutations are common in mast cell neoplasms and GISTs. Indeed, both of mast cell neoplasms and GISTs have the same exon 8 c-kit gene mutations, at least Del-Asp419 and ThrTyrAsp (417-419) Tyr. The cause of tumor-type specificity in Asp816Val remains to be clarified.

Finally, we showed that GISTs with exon 8 c-kit gene mutations might have features of extragastric development and metastasis-prone nature. Since the exon 8 c-kit gene mutations appeared to be sensitive to imatinib, accurate genotyping including not only exons 9, 11, 13 and 17 but also exon 8 of the c-kit gene is necessary to predict response to imatinib in both unresectable/metastatic and adjuvant settings.

Acknowledgements

This work was partly supported by Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (Grant No. 23390094).

Disclosure of conflict of interest

Seiichi Hirota received research fund from Novartis Pharma K.K., Japan. The other authors have no conflict of interest.

Address correspondence to: Dr. Seiichi Hirota, Department of Surgical Pathology, Hyogo College of Medicine, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo 663-8501, Japan. Tel: +81-798-45-6667; Fax: +81-798-45-6671; E-mail: hiros@hyo-med.ac.jp

References

Exon 8 c-kit gene mutation in GISTs


Exon 8 c-kit gene mutation in GISTs


